Phase II study of dasatinib in patients with previously treated malignant mesothelioma (Cancer and leukemia group B 30601): A brief report

Journal of Thoracic Oncology

Volumn 7, Issue 4, 2012, Pages 755-759

  Dudek, Arkadiusz Z ^a   Pang, Herbert ^b   Kratzke, Robert A ^a   Otterson, Gregory A ^c   Hodgson, Lydia ^b   Vokes, Everett E ^d   Kindler, Hedy L ^d  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

Dasatinib; Mesothelioma; SRC kinase

Indexed keywords

COLONY STIMULATING FACTOR 1; DASATINIB; MESOTHELIN; PLATELET DERIVED GROWTH FACTOR B; VASCULOTROPIN;

ADULT; ADVERSE OUTCOME; AGED; ANEMIA; ARTICLE; CANCER CONTROL; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; HUMAN; LYMPHOCYTOPENIA; MALE; MALIGNANT MESOTHELIOMA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES;

EID: 84858789713     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318248242c     Document Type: Article

References (13)

1. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-2644. (Pubitemid 46606305)
2. Gnoni A, Marech I, Silvestris N, et al. Dasatinib: an anti-tumour agent via Src inhibition. Curr Drug Targets 2011;12:563-578.
3. Zucali PA, Ceresoli GL, De Vincenzo F, et al. Advances in the biology of malignant pleural mesothelioma. Cancer Treat Rev 2011;37: 543-558.
4. Lee AW, States DJ. Both src-dependent and independent mechanisms mediate phosphatidylinositol 3-kinase regulation of colony-stimulating factor 1-activated mitogen-activated protein kinases in myeloid progenitors. Mol Cell Biol 2000;20:6779-6798.
5. Wheatley-Price P, Yang B, Patsios D, et al. Soluble mesothelin-related peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol 2010;28:3316-3322.
6. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004;15:257-260. (Pubitemid 38262625)
7. Dubey S, Jänne PA, Krug L, et al. A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thorac Oncol 2010;5:1655-1661.
8. Jassem J, Ramlau R, Santoro A, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008;26:1698-1704.
9. Kowalska M, Tajer J, Chechlinska M, et al. Serum macrophage colony-stimulating factor (M-CSF) in patients with Hodgkin lymphoma. Med Oncol. 2011, June 30.
10. Mroczko B, Groblewska M, Wereszczy?nska-Siemiatkowska U, et al. Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis. Clin Chim Acta 2007;380:208-212. (Pubitemid 46498063)
11. Ide H, Hatake K, Terado Y, et al. Serum level of macrophage colony-stimulating factor is increased in prostate cancer patients with bone metastasis. Hum Cell 2008;21:1-6.
12. Kaminska J, Kowalska M, Kotowicz B, et al. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF-an independent prognostic factor. Oncology 2006;70:115-125. (Pubitemid 43760337)
13. Bourgin-Hierle C, Gobert-Gosse S, Thérier J, et al. Src-family kinases play an essential role in differentiation signaling downstream of macrophage colony-stimulating factor receptors mediating persistent phosphorylation of phospholipase C-gamma2 and MAP kinases ERK1 and ERK2. Leukemia 2008;22:161-169.